Accordingly, our study aimed to investigate the functional behavior of these KRAS and PIK3CA cancer-driver genes along with identifying the somatic mutations associated with the aggressive benign tumor in the developed immortalized endometriotic epithelial cell line, HMOsisEC10. This evidence concerns the gene KRAS and benign neoplasm.